Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

About this update from Indivior Pharmaceuticals, Inc.

[{"type":"text","content":"SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares (\"Ordinary Shares\") on the Equity Shares (Transition) category of the Official List (the \"Official List\") of the U.K. Financial Conduct Authority (\"FCA\"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's (\"LSE\") main market for listed securities (together, the \"London Delisting\").\n\n \n \n \n \n \n \n\n \nBackground to and Reasons for the London Delisting \nIn the circular published by Indivior on May 3, 2024, the Board noted its intention to maintain the Company's secondary listing in London, \"for as long as it is considered to be in the best interests of Indivior and its shareholders as a whole.\"\nFollowing the completion of Indivior's transition to a U.S. primary listing, the Board has kept its listing structure under regular review. As part of such review, the Company has considered, among other things, the liquidity and trading volumes of Ordinary Shares on each of the Nasdaq Stock Market (\"Nasdaq\") and the LSE, the location of its shareholders, as well as the cost and administrative requirements related to its secondary listing in London. \nIn further consideration of Indivior's listing structure, the Board now believes that the London Delisting will be beneficial for the following reasons:\nFully aligns with Indivior's most attractive and valuable opportunity set – U.S. SUBLOCADE;Better reflects the Company's geographic net revenue profile; over 80% of net revenue is generated from the U.S.;Eliminates the cost and complexity of maintaining a secondary listing;Recognizes that liquidity on Nasdaq now far outweighs liquidity on the LSE; as of May 27th, trading on the Nasdaq now accounts for approximately 75% of total trading volume across both exchanges over the last 30 days;Takes account of the location of most holders of Ordinary Shares by value; over 70% are now held by shareholders located in the U.S.; andPermits timing of material news announcements that aligns with the Company's U.S. peer set.Accordingly, the Company hereby gives notice that it has requested that: (i) the FCA cancel the listing of the Ordinary Shares on the Equity Shares (Transition) category of the Officia...

More updates from Indivior Pharmaceuticals, Inc.